title: Genetic heterogeneity in HER2 testing may influence therapy eligibility.
abstract: Prospective studies have demonstrated that approximately 20% of HER2 testing may be inaccurate. When carefully validated testing is conducted, available data do not clearly demonstrate the superiority of either IHC or fluorescence in situ hybridization (FISH) as a predictor of benefit from anti-HER2 therapy. In addition, the interpretation of the findings of HER2 tests according to international guidelines is not uniform. The American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) recently published practice guidelines for a definition of HER2 amplification heterogeneity that can give rise to discrepant results between IHC and FISH assays for HER2. In this article, we compare the HER2 status of 291 non consecutive breast cancers. The status is determined by both IHC and FISH approaches, using a specific FISH strategy to investigate genetic heterogeneity. Our data demonstrate that HER2 amplified cells may be found as diffuse, clustered in a specific area or section, intermingled with non-amplified cells or confined to metastatic nodules. The correct evaluation of ratio value in the presence of genetic heterogeneity and of polysomy contributes to the accurate assessment of HER2 status and potentially affects the selection of appropriate anti-HER2 therapy. By taking into account the presence of different genetic cell populations, the immunotherapy eligibility criteria for HER2 FISH scoring proposed in the CAP (2009) and SIGU guidelines identify an additional subset of cases for trastuzumab or lapatinib therapy compared to the ASCO/CAP (2007) guidelines.
authors: Department of Human Morphology, Section of Anatomic Pathology, University of Insubria and Ospedale di Circolo, Via O. Rossi, 9, 21100 Varese, Italy. barbara1.bernasconi@uninsubria.it
authors: Barbara
authors: B
authors: Bernasconi
authors: Anna Maria
authors: AM
authors: Chiaravalli
authors: Giovanna
authors: G
authors: Finzi
authors: Katia
authors: K
authors: Milani
authors: Maria Grazia
authors: MG
authors: Tibiletti
mesh_terms: D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics*; D018567:Breast Neoplasms, Male / Q000188:drug therapy / Q000235:genetics*; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy / Q000235:genetics*; D005260:Female; D005784:Gene Amplification; D018740:Genetic Heterogeneity; D005820:Genetic Testing; D006801:Humans; D007150:Immunohistochemistry; D017404:In Situ Hybridization, Fluorescence; D008297:Male; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy / Q000235:genetics*; D017410:Practice Guidelines as Topic; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics*
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human